Abasaglar ® (basal insulin glargine)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information: Abasaglar Summary of Product Characteristics (SmPC)

Abasaglar® (insulin glargine): Intravenous Use

Abasaglar is administered subcutaneously and should not be administered intravenously.

Detailed Information

After injection of Abasaglar into the SC tissue, the acidic solution is neutralized, leading to formulation of micro-precipitates from which small amounts of Abasaglar are continuously released.1

Abasaglar has a slow and prolonged absorption and a relatively constant concentration/time profile over 24 hours with no pronounced peak.2

Special Warnings And Precautions For Use

Abasaglar is not the insulin of choice for the treatment of DKA. Instead, regular insulin administered intravenously is recommended in such cases.1

References

1. Abasaglar [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

2. Data on file, Eli Lilly and Company and/or one of its subsidiaries.

Glossary

Abasaglar = Abasaglar® (insulin glargine) 100 units/mL

DKA = diabetic ketoacidosis

SC = subcutaneous

Date of Last Review: April 02, 2019


Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 8am - 4pm, excluding Bank Holidays

Or you can

Chat with Us If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a question